Although the competition in the pharmaceutical investment industry is increasing day by day, the road to attracting pharmaceutical products is not as complicated as we think. Our other companies that are still confused can flexibly learn from their own different circumstances. The drug investment market has always been a special market with heavy margins that rely on production and dissimilation to achieve profitability. Fortunately, some companies in the industry with a keen sense of market have achieved a better breakthrough and established The unique "pharmaceutical specialty marketing" of drug investment, high profitability is accompanied by high risks.

First of all, the drug investment network points out that the most important thing for enterprises to differentiate their drug operations is positioning. Blue Ocean has everywhere to see who can be subdivided. Once an effective subdivision is made out of this block, enterprises can use the preemptive market competition form to separate the later companies and enjoy the high profits of Blue Ocean. In fact, the differentiated positioning of enterprises mentioned here includes many aspects. The unique positioning of the company's own products in operation, as well as the unique positioning of the company's operating channels, also includes the positioning of the specialty medicines for investment in various aspects such as service and marketing.

Second, the introduction of pharmaceutical investment network, companies must carefully integrate their own advantages of resources. Enterprises must be clear where they have long been in the advantage of the business investment process. Is the product features, has a number of exclusive varieties, new special drug varieties and health insurance varieties? Or channel operation features, in clinical, specialist, hype or OTC pharmacy, etc. have their own channel to take the scale or grasp, these can be used as the first choice for companies to implement differentiated positioning, to guide business operations.

Finally, some of the new channels that have emerged in the increasingly fragmented market are also well-found and exploitable by us. For investment companies that cannot achieve product production by themselves and do not have market control, the dependence on products is obvious. These varieties are as scarce as the resources they hope to acquire as any drug investment enterprise in the drug investment industry. At the same time, now manufacturers continue to skip traditional businesses and build self-built team development terminals.